CriticalSelective 5-HT1B/1D serotonin receptor agonist×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Rizatriptan and sumatriptan stimulate serotonin 5-HT1B and 5-HT1D receptors (sumatriptan mainly the vascular 5-HT1D receptor), and stimulation of these receptors can constrict cranial blood vessels (rizatriptan and sumatriptan summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Their effects add up, and according to the Spanish rizatriptan SmPC this raises the risk of coronary artery constriction and hypertensive effects (AEMPS, section 4.5). The sumatriptan SmPC states that data on such combinations are limited, that the higher risk of coronary vasospasm is theoretical and that the effects may be additive. According to the same SmPC, the interval needed between sumatriptan and another triptan is unknown and depends on the doses and products used (AEMPS, section 4.5). The US Food and Drug Administration (FDA) labels of both drugs give possible additive vasospastic effects as the reason for the contraindication (section 7.3). The documents give no data on either drug changing the levels of the other.
Symptoms
5-HT1B/1D receptor agonists have been associated with coronary artery spasm and, rarely, with myocardial ischaemia and infarction (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Each of the two drugs can itself cause chest tightness and pain, sometimes intense and spreading to the throat, palpitations and raised blood pressure (rizatriptan and sumatriptan SmPCs, AEMPS, sections 4.4 and 4.8). Life-threatening heart rhythm disturbances have been reported within a few hours of taking 5-HT1 agonists, and on rare occasions hypertensive crisis with acute impairment of organ systems. Spasm of other arteries causes ischaemia of the limbs and bowel, with abdominal pain and bloody diarrhoea (rizatriptan label, US Food and Drug Administration, FDA, sections 5.2, 5.5 and 5.8).
Management
The combination is contraindicated. The Spanish rizatriptan summary of product characteristics (SmPC) names sumatriptan among the 5-HT1B/1D receptor agonists that must not be used with rizatriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The Spanish sumatriptan SmPC contraindicates sumatriptan with any triptan (AEMPS, section 4.3). The US Food and Drug Administration (FDA) labels of both drugs contraindicate a second 5-HT1 agonist within 24 hours (sections 4 and 7.3). Take sumatriptan no earlier than 24 hours after another triptan, and another triptan no earlier than 24 hours after sumatriptan (sumatriptan SmPC, AEMPS, section 4.5; FDA labels, section 4). The Spanish rizatriptan SmPC gives no such interval. If the first triptan dose does not help, do not take a second dose for the same attack. According to the sumatriptan SmPC, such an attack can be treated with paracetamol, acetylsalicylic acid or non-steroidal anti-inflammatory drugs (rizatriptan and sumatriptan SmPCs, AEMPS, section 4.2). Rizatriptan is contraindicated in moderately severe or severe hypertension and in untreated mild hypertension, and sumatriptan in moderate and severe hypertension and in uncontrolled mild hypertension (rizatriptan and sumatriptan SmPCs, AEMPS, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further doses and assess the patient (rizatriptan and sumatriptan SmPCs, AEMPS, section 4.4). Stop the triptan if heart rhythm disturbances occur (FDA labels, section 5.2). Taking triptans, ergotamine or a combination of them on 10 or more days a month may make headaches more frequent, up to daily headache. The overused drugs may then need to be withdrawn (FDA labels, section 5.6).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Rizatriptán (nº registro 62289), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62289 (Maxalt 10 mg comprimidos, Organon Salud), revisión 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: MAXALT (rizatriptan benzoate) prescribing information (2026)– FDA, DailyMed setid 007b4644-e0e7-4863-9ae3-fe09676b3f5f (Organon), revisión 01/2026 (versión 4), secciones 4, 5.2, 5.5, 5.6, 5.8 y 7.2
- AEMPS: Ficha técnica: Sumatriptán, Imigran Neo 50 mg (nº registro 66406), sección 4.3 (2025)– AEMPS, CIMA, nº registro 66406 (Imigran Neo 50 mg comprimidos recubiertos con película, GlaxoSmithKline), revisión 10/2025 (la sección 10 indica 08/2025), secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: IMITREX tablets (sumatriptan) prescribing information (2025)– FDA, DailyMed setid 584abe73-8290-4484-ff8e-5890831c095e (GlaxoSmithKline), revisión 12/2025 (versión 24), secciones 4, 5.7, 5.8, 7.2 y 12.3